Smith, M.P. et al. have reported that MAPKi therapy leads to increased infiltration of melanoma by TAM that, through TNF release, induce MAPKi resistance and promote cell survival via enhanced NF-κB signaling and upregulation of downstream lineage transcription factor MITF [10]. This evidence concerns the gene TNF and melanoma.